Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

“…[36], stwierdzono, że łączna częstość występowania kardiotoksyczności po leczeniu antracyklinami wyniosła 9%, a 98% przypadków wystąpiło w ciągu Tabela 1. Częstość występowania dysfunkcji lewej komory związanej z lekami wykorzystywanymi w terapii przeciwnowotworowej [10][11][12][13][14][15][16][17][18][19][20][21] [37]. Co więcej, jeżeli dysfunkcja serca związana ze stosowaniem antracyklin zostanie wykryta wcześnie i zastosuje się farmakoterapię HF, u pacjentów często obserwuje się znaczną poprawę czynnościową.…”

Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method

“…None of the participants in our study exhibited progressive cardiac dysfunction. Still, the technique may be a useful means of evaluating irreversible myocardial injury in patients receiving trastuzumab following anthracycline, as prior anthracycline exposure is reportedly a risk factor for trastuzumab-related cardiotoxicity alongside concomitant radiation therapy and general cardiovascular risk factors (such as older age, obesity, smoking, dyslipidemia, hypertension, diabetes mellitus and history of coronary artery disease) [3,26,27]. In our cohort of patients with breast cancer, the LVEF measured by CMR tended to decrease at 3 months, and had significantly decreased by 6 months after the initiation of trastuzumab.…”

Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment

“…To realise the potential of breast cancer treatments, cancer clinicians need assessment strategies that enable them to accurately identify treatment-related and pre-existing cardiac risks and to modify their combined potential to induce heart disease in breast cancer patients [10]. Given that a normal left ventricular ejection fraction at baseline cannot exclude the possibility of subsequent cardiotoxicity, serial cardiac imaging to assess left ventricular function is usually performed to identify patients who develop cardiotoxicity; however, outcomes are generally poor once a patient develops clinical heart failure [10].…”

“…Given that a normal left ventricular ejection fraction at baseline cannot exclude the possibility of subsequent cardiotoxicity, serial cardiac imaging to assess left ventricular function is usually performed to identify patients who develop cardiotoxicity; however, outcomes are generally poor once a patient develops clinical heart failure [10].…”